Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase 2 4Phase 3 2

Status

Completed 4Recruiting 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Classical hematology 4Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Breast Neoplasms 1278Carcinoma, Non-Small-Cell Lung 927Prostatic Neoplasms 729Neoplasms 633Multiple Myeloma 554Lymphoma 540Colorectal Neoplasms 530Lung Neoplasms 515Leukemia 498Leukemia, Myeloid, Acute 474Neoplasm Metastasis 471Melanoma 426Lymphoma, Non-Hodgkin 420Ovarian Neoplasms 417Leukemia, Lymphocytic, Chronic, B-Cell 386Pancreatic Neoplasms 373Recurrence 338Precursor Cell Lymphoblastic Leukemia-Lymphoma 329Head and Neck Neoplasms 307Lymphoma, Large B-Cell, Diffuse 295Glioblastoma 294Myelodysplastic Syndromes 288Lymphoma, Follicular 287Brain Neoplasms 287Stomach Neoplasms 282Carcinoma, Renal Cell 268Carcinoma, Hepatocellular 262Hodgkin Disease 261Rectal Neoplasms 256Sarcoma 250

Interventions

Fentanyl 2fludarabine phosphate 1Whole-Body Irradiation 1Thiotepa 1Melphalan 1Cyclophosphamide 1Busulfan 1Antilymphocyte Serum 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Completed × Anemia, Sickle Cell × Clear all
NCT01895361 2020-01-31

SUSTAIN

Reprixys Pharmaceutical Corporation

Phase 2 Completed
198 enrolled 18 charts 1 FDA
Classical hematology

Anemia, Sickle Cell, Priapism

NCT01049854 2018-08-21

CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant

New York Medical College

Phase 2 Completed
20 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Bone Marrow Failure Disorders, Anemia, Sickle Cell, Immunologic Deficiency Syndromes, Leukemia, Lymphoma, Metabolism, Inborn Errors, Histiocytosis, beta-Thalassemia

NCT00236041 2014-05-09

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
38 enrolled
Classical hematology

Agnosia, Anemia, Sickle Cell, Burns, Neoplasms, Breakthrough Pain

NCT00236093 2014-05-09

Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
Classical hematology

Anemia, Sickle Cell, Burns, Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡